E-LIB Suche - Ergebnisse für: Neil McAuslane

1

Regulatory, health technology assessment and company intera..:

Wang, Ting ; McAuslane, Neil ; Goettsch, Wim G...
International Journal of Technology Assessment in Health Care. 39 (2023) 1 - p. , 2023

Link: https://doi.org/10.1017/..

2

An Evaluation of the Swissmedic Regulatory Framework for Ne..:

Bujar, Magda ; Dalla Torre di Sanguinetto, Simon Andreas ; Kermad, Adem..
Therapeutic Innovation & Regulatory Science. 58 (2023) 1 - p. 153-165 , 2023

Link: https://doi.org/10.1007/..

3

OP136 A Comparison Of Health Technology Assessment Recommen..:

Wang, Tina ; Solar, Belen ; McAuslane, Neil
International Journal of Technology Assessment in Health Care. 39 (2023) S1 - p. S40-S40 , 2023

Link: https://doi.org/10.1017/..

4

Evaluation of Risk-Based Approaches to the Registration of ..:

McAuslane, Neil ; Bujar, Magda ; Sithole, Tariro...
Pharmaceutical Medicine. , 2023

Link: https://doi.org/10.1007/..

5

Building HTA insights into the drug development plan: Curre..:

Wang, Ting ; McAuslane, Neil ; Gardarsdottir, Helga..
Drug Discovery Today. 27 (2022) 1 - p. 347-353 , 2022

Link: https://doi.org/10.1016/..

6

Challenges and Opportunities for Companies to Build HTA/Pay..:

Wang, Ting ; McAuslane, Neil ; Goettsch, Wim G...
Frontiers in Pharmacology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

7

PD63 Impact Of Parallel Submission On The Rollout Time and ..:

Sola-Barrado, Belen ; Wang, Tina ; McAuslane, Neil
International Journal of Technology Assessment in Health Care. 38 (2022) S1 - p. S113-S113 , 2022

Link: https://doi.org/10.1017/..

8

Evaluation of the Performance of the Gulf Cooperation Counc..:

Hashan, Hajed M. ; Al-Muteb, Sarah K. ; Alismail, Ibrahim A....
Pharmaceutical Medicine. 36 (2022) 4 - p. 223-231 , 2022

Link: https://doi.org/10.1007/..

9

PD47 Associations Of Orphan Designation And Other Drug Deve..:

Sola-Barrado, Belen ; Wang, Tina ; McAuslane, Neil
International Journal of Technology Assessment in Health Care. 38 (2022) S1 - p. S107-S108 , 2022

Link: https://doi.org/10.1017/..

10

The Qualitative Value of Facilitated Regulatory Pathways in..:

Bujar, Magdalena ; McAuslane, Neil ; Liberti, Lawrence
Pharmaceutical Medicine. 35 (2021) 2 - p. 113-122 , 2021

Link: https://doi.org/10.1007/..

11

Transparency in European Medicines Agency and US Food and D..:

Bujar, Magda ; Ferragu, Sara ; McAuslane, Neil..
Clinical Therapeutics. 43 (2021) 5 - p. 888-905 , 2021

Link: https://doi.org/10.1016/..

12

Quality Decision-Making Practices in Pharmaceutical Compani..:

Bujar, Magdalena ; McAuslane, Neil ; Connelly, Patricia.
Therapeutic Innovation & Regulatory Science. 54 (2020) 6 - p. 1404-1415 , 2020

Link: https://doi.org/10.1007/..

13

Companies' Health Technology Assessment Strategies and Prac..:

Wang, Ting ; McAuslane, Neil ; Liberti, Lawrence...
Frontiers in Pharmacology. 11 (2020) - p. , 2020

Link: https://doi.org/10.3389/..

14

A Baseline Analysis of Regulatory Review Timelines for ANVI..:

Patel, Prisha ; Cerqueira, Daniela Marreco ; Santos, Gustavo Mendes Lima...
Therapeutic Innovation & Regulatory Science. 54 (2020) 6 - p. 1428-1435 , 2020

Link: https://doi.org/10.1007/..

15

An evaluation of the Caribbean regulatory system centralize..:

Liberti, Lawrence ; Extavour, Rian Marie ; Patel, Prisha.
Journal of Pharmaceutical Policy and Practice. 13 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..